tetano
Editor, Senior Moderator
Inflamm Res
. 2020 May 28.
doi: 10.1007/s00011-020-01366-6. Online ahead of print.
The Unleashing of the Immune System in COVID-19 and Sepsis: The Calm Before the Storm?
Salvatore Bellinvia[SUP] 1 [/SUP], Christopher J Edwards[SUP] 2 [/SUP], Matteo Schisano[SUP] 3 [/SUP], Paolo Banfi[SUP] 4 [/SUP], Matteo Fallico[SUP] 5 [/SUP], Paolo Murabito[SUP] 6 [/SUP]
Affiliations
Abstract
The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.
Keywords: Checkpoint inhibitors; Covid-19; Cytokine storm; Immune dysregulation; Inflammatory receptors; Sepsis.
. 2020 May 28.
doi: 10.1007/s00011-020-01366-6. Online ahead of print.
The Unleashing of the Immune System in COVID-19 and Sepsis: The Calm Before the Storm?
Salvatore Bellinvia[SUP] 1 [/SUP], Christopher J Edwards[SUP] 2 [/SUP], Matteo Schisano[SUP] 3 [/SUP], Paolo Banfi[SUP] 4 [/SUP], Matteo Fallico[SUP] 5 [/SUP], Paolo Murabito[SUP] 6 [/SUP]
Affiliations
- PMID: 32468151
- DOI: 10.1007/s00011-020-01366-6
Abstract
The novel coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is sorely testing health care systems and economies around the world and is rightly considered as the major health emergency in a century. Despite the course of the disease appearing to be mild in many cases, a significant proportion of symptomatic patients develop pneumonia requiring hospitalisation or progress to manifest respiratory complications leading to intensive care treatment. Potential interventions for SARS-CoV2-associated pneumonia are being tested, some of which holding promise, but as of today none of these has yet demonstrated outstanding efficacy in treating COVID-19. In this article, we discuss fresh perspectives and insights into the potential role of immune dysregulation in COVID-19 as well as similarities with systemic inflammatory response in sepsis and the rationale for exploring novel treatment options affecting host immune response.
Keywords: Checkpoint inhibitors; Covid-19; Cytokine storm; Immune dysregulation; Inflammatory receptors; Sepsis.